{"id":"dara-sc","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Infusion-related reactions"},{"rate":"15-25","effect":"Neutropenia"},{"rate":"10-15","effect":"Anemia"},{"rate":"10-15","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Upper respiratory tract infection"},{"rate":"10-15","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daratumumab binds to CD38, a surface antigen highly expressed on multiple myeloma cells, leading to cell death via antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). The subcutaneous formulation provides improved convenience and tolerability compared to intravenous administration while maintaining efficacy.","oneSentence":"Dara SC (daratumumab subcutaneous) is a monoclonal antibody that targets CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:42.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"},{"name":"Light chain myeloma"}]},"trialDetails":[{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT05083169","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-14","conditions":"Multiple Myeloma","enrollment":587},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":"Multiple Myeloma, Renal Failure","enrollment":30},{"nctId":"NCT06627309","phase":"","title":"Rapid dFLC Response Predict CHR in AL Amyloidosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10-26","conditions":"Systemic AL Amyloidosis","enrollment":50},{"nctId":"NCT06083922","phase":"PHASE2","title":"A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-16","conditions":"Multiple Myeloma, Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT06100237","phase":"PHASE2","title":"Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)","status":"RECRUITING","sponsor":"Carl Ola Landgren, MD, PhD","startDate":"2023-12-04","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT03180736","phase":"PHASE3","title":"Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2017-06-14","conditions":"Multiple Myeloma","enrollment":304},{"nctId":"NCT07274462","phase":"PHASE4","title":"DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Martin","startDate":"2025-11-01","conditions":"Microvascular Inflammation - MVI in Kindey Transplant Recipients","enrollment":20},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT05511428","phase":"PHASE4","title":"Home Based Daratumumab Administration for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-11-08","conditions":"Plasma Cell Myeloma","enrollment":20},{"nctId":"NCT05572229","phase":"PHASE2","title":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-12-21","conditions":"Multiple Myeloma","enrollment":74},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT03993912","phase":"PHASE3","title":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2019-10-17","conditions":"Multiple Myeloma","enrollment":294},{"nctId":"NCT07107529","phase":"PHASE2","title":"Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.","status":"NOT_YET_RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-10","conditions":"Multiple Myeloma (MM)","enrollment":150},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT05561387","phase":"PHASE3","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-10-12","conditions":"Plasma Cell Myeloma","enrollment":510},{"nctId":"NCT02519452","phase":"PHASE1","title":"A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-22","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT03277105","phase":"PHASE3","title":"A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":"Multiple Myeloma","enrollment":522},{"nctId":"NCT03871829","phase":"PHASE2","title":"Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-31","conditions":"Multiple Myeloma","enrollment":88},{"nctId":"NCT05849610","phase":"PHASE2","title":"Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-09-21","conditions":"High-Risk de Novo Multiple Myeloma","enrollment":30},{"nctId":"NCT06418477","phase":"PHASE2","title":"Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-06-15","conditions":"Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT06505369","phase":"PHASE2","title":"Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients","status":"RECRUITING","sponsor":"North Estonia Medical Centre","startDate":"2024-06-19","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT06455748","phase":"NA","title":"Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study","status":"RECRUITING","sponsor":"Yongyong MA","startDate":"2024-03-01","conditions":"Amyloid Light-chain Amyloidosis","enrollment":20},{"nctId":"NCT04956302","phase":"PHASE1","title":"Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Abdullah Khan","startDate":"2021-09-27","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":1},{"nctId":"NCT03242889","phase":"PHASE1","title":"A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2017-08-10","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT05408026","phase":"PHASE1, PHASE2","title":"Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM","status":"WITHDRAWN","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2022-10-01","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT04150692","phase":"PHASE2","title":"Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2021-01-08","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02951819","phase":"PHASE2","title":"A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-11-09","conditions":"Multiple Myeloma","enrollment":101},{"nctId":"NCT05054478","phase":"PHASE2","title":"Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10","conditions":"Plasma Cell Leukemia","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dara SC","genericName":"Dara SC","companyName":"Janssen Research & Development, LLC","companyId":"janssen-research-development-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dara SC (daratumumab subcutaneous) is a monoclonal antibody that targets CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Light chain myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}